Form 4 Filing for Contineum Therapeutics, Inc.

Evert B. Schimmelpennink, a director at Contineum Therapeutics, Inc., was granted a stock option for 19,000 shares of Class A Common Stock on June 26, 2026. This option, granted under the Issuer's 2024 Equity Incentive Plan, has an exercise price of $14.19 per share and will vest in full on June 26, 2027, or the next annual stockholder meeting, provided Schimmelpennink continues his service. The option expires on June 25, 2036. This transaction is reported on Form 4.